These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17306602)

  • 21. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
    Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
    Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.
    Watanabe M; Nakashima M; Togano T; Higashihara M; Watanabe T; Umezawa K; Horie R
    Biochem Biophys Res Commun; 2008 Nov; 376(2):310-4. PubMed ID: 18782563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion.
    Mino K; Ozaki M; Nakanishi K; Haga S; Sato M; Kina M; Takahashi M; Takahashi N; Kataoka A; Yanagihara K; Ochiya T; Kamiyama T; Umezawa K; Todo S
    Cancer Sci; 2011 May; 102(5):1052-8. PubMed ID: 21288284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
    Ohsugi T; Horie R; Kumasaka T; Ishida A; Ishida T; Yamaguchi K; Watanabe T; Umezawa K; Urano T
    Carcinogenesis; 2005 Aug; 26(8):1382-8. PubMed ID: 15831528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
    Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
    Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes.
    Cardile V; Libra M; Caggia S; Frasca G; Umezawa K; Stivala F; Mazzarino MC; Bevelacqua Y; Coco M; Malaponte G
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):679-83. PubMed ID: 20337659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
    Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
    J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
    Lampiasi N; Azzolina A; Umezawa K; Montalto G; McCubrey JA; Cervello M
    Cancer Lett; 2012 Sep; 322(1):35-44. PubMed ID: 22343223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The NO TRAIL to YES TRAIL in cancer therapy (review).
    Lee JY; Huerta-Yepez S; Vega M; Baritaki S; Spandidos DA; Bonavida B
    Int J Oncol; 2007 Oct; 31(4):685-91. PubMed ID: 17786298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102.
    Ohsugi T; Kumasaka T; Ishida A; Ishida T; Horie R; Watanabe T; Umezawa K; Yamaguchi K
    Leuk Res; 2006 Jan; 30(1):90-7. PubMed ID: 16002138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of nitric oxide in cancer.
    Bonavida B; Khineche S; Huerta-Yepez S; Garbán H
    Drug Resist Updat; 2006 Jun; 9(3):157-73. PubMed ID: 16822706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
    Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
    Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
    Ohsugi T; Kumasaka T; Okada S; Ishida T; Yamaguchi K; Horie R; Watanabe T; Umezawa K
    Cancer Lett; 2007 Nov; 257(2):206-15. PubMed ID: 17764832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.
    Kikuchi E; Horiguchi Y; Nakashima J; Kuroda K; Oya M; Ohigashi T; Takahashi N; Shima Y; Umezawa K; Murai M
    Cancer Res; 2003 Jan; 63(1):107-10. PubMed ID: 12517785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-kappaB-expressing and drug-resistant tumor cells.
    Manna SK; Gangadharan C
    Mol Immunol; 2009 Apr; 46(7):1340-50. PubMed ID: 19128834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
    Yasuda A; Kondo S; Nagumo T; Tsukamoto H; Mukudai Y; Umezawa K; Shintani S
    Oral Oncol; 2011 May; 47(5):334-9. PubMed ID: 21459660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
    Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
    Meng Z; Mitsutake N; Nakashima M; Starenki D; Matsuse M; Takakura S; Namba H; Saenko V; Umezawa K; Ohtsuru A; Yamashita S
    Endocrinology; 2008 Nov; 149(11):5357-65. PubMed ID: 18653704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
    Suzuki E; Ninomiya Y; Umezawa K
    Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.